Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
$30 million convertible note financing co-led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, and Westlake Village BioPartners expands investor base to include leading US life science